Want to see HUMA full AI Analyst Report?
HUMA Stock Chart & Stats
$0.70
-$0.01(-2.16%)
At close: 4:00 PM EDT
$0.70
-$0.01(-2.16%)
Day’s Range― - ―
52-Week Range$0.34 - $1.90
Previous CloseN/A
Volume2.57M
Average Volume (3M)5.32M
Market Cap
$111.42M
Enterprise Value$168.89M
Total Cash (Recent Filing)$79.90M
Total Debt (Recent Filing)$66.18M
Price to Earnings (P/E)―
Beta3.15
Next Earnings
Nov 06, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding277,798,100
10 Day Avg. Volume8,957,296
30 Day Avg. Volume5,316,757
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)48.86
Price to Sales (P/S)74.54
P/FCF Ratio-1.43
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue79.63
Enterprise Value/Gross Profit-11.94
Enterprise Value/Ebitda-2.13
Forecast
1Y Price Target
$1.75Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$3.51M
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressThe statistically significant interim result supports ATEV’s clinical differentiation in dialysis access, while the planned supplemental BLA and priority-review request provide a defined regulatory pathway. Together, these milestones can support broader adoption and future commercialization over the next several quarters.
Early Commercial AdoptionAdoption across major health systems indicates that commercialization is progressing beyond isolated sales and creates a potential base for repeat utilization. The rebuilt commercial organization and national-account strategy could improve market access as the company expands physician and hospital engagement.
Platform ExpansionCTEV extends Humacyte’s tissue-engineering platform into coronary bypass applications, broadening the potential product pipeline beyond dialysis access. FDA acceptance of the IND and completed commercial-scale lot reduce key development hurdles and establish a path toward clinical validation.
Bears Say
Persistent Losses And Cash BurnLarge ongoing losses and deeply negative operating and free cash flow show that current commercial activity is not yet funding the business. Continued clinical development, manufacturing, and selling costs may require additional financing before revenue reaches a self-sustaining scale.
Limited Commercial Scale And Cost PressureAlthough sales are growing rapidly from a small base, absolute revenue remains insufficient to offset operating expenses and manufacturing overhead. Elevated COGS and inventory reserves also indicate that near-term gross-profit conversion remains difficult as commercialization scales.
Leveraged And Volatile Balance SheetMeaningful leverage combined with historically volatile equity levels reduces financial flexibility while the company remains loss-making. This structure can constrain investment in clinical and commercial programs and increase dependence on future financing to support operations.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.34 and its highest was $1.90 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $111.42M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Nov 06, 2026 which is in 16 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Aug 12, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.113 by -$0.047.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.1.
How many shares outstanding does Humacyte have?
Humacyte has 277,798,100 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.113. Following the earnings report the stock price went down -6.338%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.75 (150.00% Upside)
$1.75 (150.00% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.68%
12-Months-Change
Fundamentals
Return on Equity
-938.20%
Trailing 12-Months
Asset Growth
-0.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Humacyte
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
HUMA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory momentum (statistically significant V012 results, planned sBLA filing, IND acceptance for CTEV, commercial team overhaul and early commercial traction) which are material positives. However, near-term financials showed modest absolute sales, rising COGS and inventory reserves, a substantial six‑month loss driven by non-cash liability remeasurements, and continued operating spend. The operational and clinical progress appears to materially outweigh the current financial headwinds, which management is positioning to address as commercialization scales.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$1.75
▲(150.00% Upside)
Technical Analysis
Ownership Overview
7.92% Insiders
4.66% Mutual Funds
0.10% Other Institutional Investors
81.69% Public Companies and
Individual Investors